Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Vaccination of SCT recipients

Bone Marrow Transplantation volume 46, page 621 (2011)Cite this article

Subjects

Last year several scientific organizations collaborated in drafting the guidelines for prevention of infections after hematopoietic SCT (HSCT).1, 2 One set of guidelines dealt with vaccination of transplant recipients and in these guidelines the conjugated heptavalent pneumococcal vaccine (PCV7; Prevnar; Pfizer Inc.) was recommended based on several studies showing both immunogenicity and safety of this vaccine in HSCT recipients. Earlier this year, a 13-valent vaccine (Prevnar13; Pfizer Inc., New York, NY, USA), which is produced in a similar way to the 7-valent vaccine, was licensed in both the USA and Europe after the completion of large clinical trials in healthy children. This vaccine contains the same seven pneumococcal serotype antigens contained in the PCV7 together with antigens from additional six serotypes. After licensure, it was decided that the heptavalent vaccine will be withdrawn from the market and therefore the published recommendations cannot be followed. Presently, a clinical trial is ongoing with this 13-valent vaccine in allogeneic HSCT recipients. In addition, a 10-valent pneumococcal vaccine (Synflorix; GlaxoSmithKline, London, UK) conjugated to another carrier protein has also been licensed in Europe for which no data yet exist in immunocompromised patients. The alternative to these conjugated vaccines is polysaccharide vaccines that have shown decreased immunogenicity compared with conjugate vaccines in allogeneic HSCT recipients. Despite the lack of data, we recommend that the 13-valent vaccine be used as replacement for the heptavalent vaccine when this is no longer available, until additional studies are performed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Ljungman P, Cordonnier C, Einsele H, Englund J, Machado CM, Storek J et al. Vaccination of hematopoietic cell transplant recipients. Bone Marrow Transplant 2009; 44: 521–526.

    Article  CAS  PubMed  Google Scholar 

  2. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143–1238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Karolinska University Hospital, Stockholm, Sweden

    P Ljungman & T N Small

Authors
  1. P Ljungman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T N Small
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the Vaccination Recommendations Writing Group

Corresponding author

Correspondence to P Ljungman.

Ethics declarations

Competing interests

Both the authors are investigators on an ongoing clinical trial with the PCV13 vaccine.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ljungman, P., Small, T. & for the Vaccination Recommendations Writing Group. Vaccination of SCT recipients. Bone Marrow Transplant 46, 621 (2011). https://doi.org/10.1038/bmt.2010.274

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.274

This article is cited by

Search

Advanced search

Quick links